New page: ==Structure of human PD-L1 in complex with inhibitor== <StructureSection load='5o45' size='340' side='right' caption='5o45, resolution 0.99Å' scene=''> == Structu... |
m Protected "5o45" [edit=sysop:move=sysop] |
(No difference)
| |
Structural highlights
Function[PD1L1_HUMAN] Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.[1] [2] Publication Abstract from PubMedBlockade of the immunoinhibitory PD-1/PD-L1 pathway using monoclonal antibodies has shown impressive results with durable clinical antitumor responses. Anti-PD-1 and anti-PD-L1 antibodies have now been approved for the treatment of a number of tumor types whereas the development of small molecules targeting immune checkpoints lags far behind. Here we characterize two classes of macrocyclic-peptide inhibitors directed at the PD-1/PD-L1 pathway. We show that these macrocyclics act by directly binding to PD-L1 and that they are capable of antagonizing PD-L1 signaling and, similarly to antibodies, can restore the function of T-cells. We also provide the crystal structures of two of these small-molecule inhibitors bound to PD-L1. The structures provide rationales for the checkpoint inhibition by these small molecules and description of their small molecule/PD-L1 interfaces provides a blueprint for design of small-molecule inhibitors of the PD-1/PD-L1 pathway. Bioactive macrocyclic inhibitors of the PD-1/PD-L1 immune checkpoint.,Magiera-Mularz K, Skalniak L, Zak KM, Musielak B, Rudzinska-Szostak E, Berlicki L, Kocik J, Grudnik P, Sala D, Zizigas-Zarganis T, Shaabani S, Domling A, Dubin G, Holak TA Angew Chem Int Ed Engl. 2017 Sep 7. doi: 10.1002/anie.201707707. PMID:28881104[3] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
| ||||||||||||||||||
This page was last modified 04:43, 21 September 2017.